Published online before print July 29, 2002, doi: 10.1161/01.HYP.0000029105.21202.FE
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2002;40:286.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
Essential Hypertension and ß2-Adrenergic Receptor Gene
Linkage and Association Analysis
From the British Heart Foundation Blood Pressure Group, Department of Medicine and Therapeutics, University of Glasgow (M.T., N.J.R.B., F.J.C., S.P., J.S.C., N.H.A., H.V.E., A.F.D.), Glasgow, United Kingdom; Department of Internal Medicine, Diabetology and Nephrology, Silesian School of Medicine (M.T., E.Z-S., B.L., W.G.), Zabrze, Poland; and Department of Medical Genetics, University of Cambridge (W.Y.S.W.), Cambridge, United Kingdom.
Correspondence to Prof Anna F. Dominiczak, British Heart Foundation Blood Pressure Group, Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, Glasgow G11 6NT, United Kingdom. E-mail ad7e{at}clinmed.gla.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
A region on human chromosome 5 (5q31.1-qter) contains several genes that encode important blood pressure regulators and thus is a good candidate for analysis of linkage and association with hypertension. We recruited 638 individuals from 212 Polish pedigrees with clustering of essential hypertension. These subjects were genotyped for 11 microsatellite markers that span this region to test for linkage to essential hypertension and systolic and diastolic blood pressures. The segment of this region of
7 cM delineated by D5S1480 and D5S500 markers was linked to blood pressures in multipoint analysis. In 2-point analysis, D5S1480—the marker in close proximity to ß2-adrenergic receptor gene—reached the maximal linkage to essential hypertension and adjusted systolic and diastolic blood pressures, implicating this gene as a positional candidate for further association studies. Arg16Gly, Gln27Glu, and Thr164Ile—3 functional single nucleotide polymorphisms within the ß2-adrenergic receptor gene—were tested for association with essential hypertension. None of these polymorphisms showed a significant association with essential hypertension, separately or in the haplotype analysis. This study provided evidence of linkage of 5q31.1-5qter region to essential hypertension in the European population. Moreover, it implicated the chromosomal segment in close proximity to D5S1480 and D5S500. The detailed analysis of 3 single nucleotide polymorphisms does not support the role of the ß2-adrenergic receptor gene as a major causative gene for the detected linkage.
Key Words: chromosomes • adrenergic receptors • genes • linkage • blood pressure
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Essential hypertension is a multifactorial complex trait with a strong hereditary component. Apart from genome-wide scans and candidate gene approach (principal methods used in pursuit of genetic loci that may determine predisposition to essential hypertension),1 a target chromosomal region approach combining the rationale of 2 major strategies has been postulated.2 Selection of a small chromosomal region implicated by genome-wide searches and containing several candidate genes pathophysiologically related to the investigated phenotypes allows for denser saturation with microsatellite markers and may be followed by subsequent positional analysis. The distal segment of the long arm of chromosome 5 (5q31.1-qter) is an outstanding target chromosomal region for studies on essential hypertension, having been linked to both systolic3 and postexercise diastolic blood pressure4 in genome-wide scans performed in white populations. Furthermore, this region contains a cluster of genes coding for proteins known as important blood pressure regulators (ß2-adrenergic receptor gene [ADRB2],
1B-adrenergic receptor, dopamine D1 receptor, annexin VI) and implicated as possible contributors to the pathogenesis of several cardiovascular disorders (platelet-derived growth factor receptor, glutathione peroxidase). We performed a linkage analysis of this region using 3 related phenotypes: a diagnosis of essential hypertension (a qualitative trait) and 2 quantitative phenotypes—systolic and diastolic blood pressure. We searched for a linkage indicating positional locus for further association analyses. One of the loci in the implicated portion of the target region, ADRB2, was subsequently analyzed in association studies.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
The participants in this project (Silesian Hypertension Study) were recruited between 1999 to 2000 in Silesia, a region in the south of Poland with a high prevalence of cardiovascular morbidity and mortality. The study was designed to investigate for genetic predisposition to several cardiovascular phenotypes and was based on collecting probands with diagnosed essential hypertension along with their available parents and/or siblings. The project was approved by the local bioethical committee, and informed consent was obtained from each participant. We recruited 638 white individuals from 212 families with clustering of essential hypertension. Complete phenotypic information was obtained from 635 subjects representing 210 families. Six other individuals from 3 families were excluded because of the inconsistencies in Mendelian segregation.
Phenotyping
Phenotyping included clinical history obtained by standardized questionnaires, physical examination, and laboratory tests according to the recommendations of the World Health Organization.5 Hypertension was defined as systolic and/or diastolic blood pressure >140/90 mm Hg on 3 separate occasions and/or remaining on antihypertensive treatment.5 Subjects with secondary forms of hypertension were excluded from the study. Height and weight measurements were taken in standard conditions to calculate body mass index. Blood pressure was taken in a sitting position using mercury sphygmomanometer with a cuff size individually adjusted to the arm after 20 minutes of rest. Systolic blood pressure was taken at the return of arterial sounds (Korotkoff phase I), and disappearance of sounds (Korotkoff phase V) indicated diastolic blood pressure. The average of 3 consecutive recordings of both systolic and diastolic blood pressure was used to obtain the representative values. Blood pressure values from subjects remaining on antihypertensive therapy were nonparametrically adjusted for treatment effect according to the algorithm used previously in analyses of Framingham data.6 In brief, the adjustments were based on a nonparametric method in which the blood pressures of an individual receiving antihypertensive treatment were shifted upward by adding to them the mean of the residues of the age-regressed blood pressures of those with higher blood pressures and the individual itself. Both genders were analyzed separately. Observations from individuals not taking antihypertensive therapy remained unchanged.
Identification and Localization of Genetic Loci Within the Candidate Chromosomal Region
Eight microsatellite markers (D5S1480, D5S636, D5s820, D5s2093, D5s1471, D5s1456, D5s462, D5s211) spanning the 35-cM region on the distal portion of long arm of chromosome 5 (5q31.1-qter) were initially selected for molecular analysis. A set of 3 additional markers (D5S500, D5S642, D5S494) located proximally from D5S1480 and covering the distance of 20 cM was chosen at a later stage to define the linkage region more accurately (Figure).
|
Location and distances between the markers were obtained from public databases, including the Center for Medical Genetics at Marshfield Medical Research Foundation (http://research.marshfieldclinic.org/genetics) and the Genetic Location Database (http://cedar.genetics.soton.ac.uk/pub/chrom5/map.htm). Candidate genes were localized within the region by use of integrated information from the Unified Database for Human Genome Mapping at the Weizmann Institute of Science (http://bioinformatics.weizmann. ac.il) and the database at University of California, Santa Cruz, Human Genome Project Working Draft (http://genome.ucsc.edu). Single nucleotide polymorphisms within the ADRB2 gene were identified using the Human Genome Variation Database (http://hgvbase.cgb.ki.se) and the Single Nucleotide Polymorphism (SNP) Database of the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/SNP/index.html) and were then prioritized based on their ability to affect the function of the receptor.
Genotyping
Genomic DNA was extracted from whole blood samples by use of the MasterPureTM DNA purification kit (Epicentre Technologies). Each microsatellite marker was amplified by polymerase chain reaction (PCR) using Tetrad DNA Engine (MJ Research). The sequences of the primers were obtained from Genome Database Bank (http://www.gdb.org) and sequenced (Applied Biosystems). The total volume of PCR master mixture was 20 µL and included 25 ng of genomic DNA, 200 µmol/L of each dNTP (Promega), 10 pmol of forward and reverse primer, 0.2 U of Taq DNA polymerase (HotStarTaq, Qiagen), 10x PCR buffer (with 1.5 mmol/L of MgCl2, Qiagen), and polyoxyethylene ether (W-1 solution, Life Technologies). The 5'-end of the forward primers was labeled with 6-carboxyfluorescein (FAM) or its fluorescent analogs (HEX, NED). DNA polymerase activation in 95°C for 1 minute was followed by 34 cycles of 94°C (1 minute), annealing (1 minute), 72°C (1 minute), and the final extension in 72°C for 10 minutes. PCR products were pooled and resolved on 5% polyacrylamide gel by use of an ABI 377 Sequencer (Applied Biosystems). Genotyping was performed by use of Genescan and Genotyper software (Applied Biosystems), independently by 2 individuals, who were unaware of phenotypic data.
PCR amplification of the DNA fragment containing Arg16Gly polymorphism of the ADRB2 gene was performed in a volume of 20 µL, including 25 ng of genomic DNA, 200 µmol/L of each dNTP (Promega), 10 pmol of forward and reverse primer, 0.2 U of Taq DNA polymerase (HotStarTaq, Qiagen), and 10x PCR buffer (with 1.5 mmol/L of MgCl2, Qiagen). DNA polymerase activation in 95°C for 15 minutes was followed by 34 cycles of denaturation (95°C, 1 minute) annealing (52°C, 1 minute), and extension (72°C, 1 minute), with a final extension (72°C, 10 minutes). The PCR product was digested with 2 U of BsrDI restriction enzyme (New England Biolabs) in 60°C for 6 hours and resolved on 3% 1000-agarose (Life Technologies) gel containing ethidium bromide, with subsequent visualization with a Fluoro-S Multi-imager (Biorad). The primers and the sizes of digestion products were the same as described previously.7
The amplification conditions for DNA fragment containing Gln27Glu polymorphism of the ADRB2 gene were similar to the Arg16Gly polymorphism, except for the primers sequence and annealing temperature (63°C). The PCR product was digested with 1.5 U of ItaI restriction enzyme (Roche) in 37°C for 20 hours, resolved on 2.5% 1000-agarose (Life Technologies) gel containing ethidium bromide, and visualized by means of a Fluoro-S Multi-imager. The sequence of the primers and the sizes of digestion products were the same as described previously.7
The PCR conditions for the segment containing the Thr164IIe SNP of the ADRB2 gene were similar to that of the Arg16Gly polymorphism except for the sequence of primers and annealing temperature (55°C). The PCR product was digested with 2 U of MnlI restriction enzyme (New England Biolabs) in 37°C for 5 hours, resolved on 2% ultra pure-agarose (Life Technologies) gel containing ethidium bromide, and visualized by means of a Fluoro-S Multi-imager. The sequence of primers and the sizes of digestion products were the same as described previously.7 Direct sequencing of the DNA fragment, including 3 functional SNPs within the ADRB2 gene, was performed in 15 randomly selected unrelated individuals to confirm the results of restriction fragment-length polymorphisms.
Statistical Analysis
Verification of genotypes for inconsistencies in Mendelian segregation was performed by means of PEDCHECK program.8 Multiple methods were used for linkage and association analysis of both qualitative and quantitative traits because this provides greater reliability of final result. Haseman-Elston regression analysis, based on regressing the siblings’ squared phenotype difference on their genetic similarity (defined as alleles shared identical by descent [IBD]) was used to test for 2-point linkage in case of microsatellite markers and the investigated phenotypes.9 Another IBD sib-pair test, SPLINK (Unix version 1.08), was applied to investigate for linkage of microsatellite markers to essential hypertension. Confirmatory 2-point linkage analysis based on estimation of alleles identical by state (IBS) at a microsatellite marker compared with the random distribution of alleles was performed for hypertension as a binary trait, by means of IBS 
2 test.10 The Haseman-Elston and IBS 2 2-point linkage tests were completed with SIB-PAIR program.11 For further confirmation of the results obtained in 2-point linkage analysis, multipoint nonparametric Z-score rank test was performed with quantitative phenotypes using MAPMAKER/SIBS.
The subsequent strategy, testing for association of essential hypertension with the ADRB2 gene as a positional candidate, was performed using family-based association tests.
The transmission disequilibrium test (TDT) assessing the number of transmitted versus non-transmitted alleles from heterozygous parents to affected (hypertensive) probands (compared with expected 50%/50% transmission/nontransmission ratio) was used to test for association of essential hypertension with the SNPs of the ADRB2.12 The results of the TDTs were then verified by means of the empirical variance-family based association test (EV-FBAT) method, determining the value of an association test under the null hypothesis of linkage but no association by use of an empirical variance-covariance estimator.13 Unlike other family-based tests, this method is not affected by pedigree configurations and can be used in case of binary, quantitative, or time-to-onset traits, as well as multi- and biallelic markers.13
Clayton’s modified TDT was performed in case of haplotype combinations, using the program TRANSMIT.14 This test calculates a score vector that is equalized over all possible combinations of parental haplotypes and transmissions, in concordance with the observed data, and deals with the problem of partially unknown parental genotypes and haplotype phase uncertainty.14
Binary logistic regression analysis was performed in the parental generation to test for association between essential hypertension and each genetic variant of the ADRB2 in the presence of other covariates, including age, gender, and body mass index.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Clinical Characteristics
There were 629 individuals (age, 45.8±15.7 years) from 207 families, with 313 (49%) men and 316 (51%) women included in the final analysis. Of these, 401 (63.7%) subjects were hypertensive, and 270 (67.3%) of the hypertensive subjects remained on treatment. The demographic and clinical data of all individuals divided into probands, parents, and siblings are shown in Table 1.
|
Linkage Studies on 5q31.1-qter
All the microsatellite markers were highly informative, with the number of alleles from 8 (D5S820, D5S462, D5S211) to 15 (D5S494), and heterozygosity from 60% (D5S462) to 82% (D5S500).
In the first set of 8 markers, there was a significant linkage of the D5S1480 microsatellite marker to essential hypertension in 2-point linkage analysis (Table 2). The other markers did not show statistically significant linkage to this phenotype. Two-point linkage analysis of systolic and diastolic blood pressures (adjusted nonparametrically for treatment effect) showed statistical significance of the same marker (Table 2).
|
In view of the marginal location of the significant marker assigning the linkage within the candidate region, we also performed similar 2-point linkage studies for a set of 3 markers located proximally from D5S1480. Two of these markers (D5S500 and D5S642) were significantly linked to essential hypertension, reaching linkage values of t=2.45 (P=0.008) and t=1.96 (P=0.03), respectively. Consistently, Haseman-Elston regression analysis of adjusted systolic and diastolic blood pressure revealed that the marker most proximal to D5S1480–D5S500 reached a borderline significance level in 2-point linkage analysis with diastolic blood pressure (P=0.06) and systolic blood pressure (P=0.09).
A joint multipoint analysis of all 11 microsatellite markers indicated that a region of 7 cM in close proximity to D5S1480 and D5S500 is linked to systolic blood pressure (Figure). The same tendency was evident in multipoint linkage analysis of adjusted diastolic blood pressure, with the maximal Z-score of 1.8 at the position of the D5S1480 marker.
Association Studies of the Positional Candidate, ADRB2 Gene
Arg16Gly, Gln27Glu, and Thr164Ile polymorphisms were not associated with essential hypertension in the TDT (Table 3). This lack of association was confirmed by EV-FBAT test (Arg16Gly, P=0.67; Gln27Glu, P=0.55). Testing for association of essential hypertension with Thr164Ile polymorphism using EV-FBAT could not be performed because of a rarity of Ile allele (only 17 individuals in the study were carriers of this allele).
|
Among 7 observed haplotypes (denoted A through G), B, D, and F represented the most common variants, comprising 97.4% of the total haplotypes (Table 4). The number of transmitted haplotypes from parents to hypertensive offspring was not significantly different from the expected number of transmissions (Table 4).
|
In the binary regression model, including age, gender, and body mass index as potential cofounders, none of the ADRB2 polymorphisms were associated with hypertension. The odds ratio for hypertension in subjects homozygous for a wild variant compared with heterozygous individuals and homozygous for a mutant allele was 0.85 (95% CI, 0.3 to 2.2; P=0.74) and 1.46 (95% CI, 0.5 to 4.2; P=0.49) for Arg16Gly, 1.33 (95% CI, 0.6 to 3.1; P=0.5) and 1.54 (95% CI, 0.5 to 4.4; P=0.43) for Gln27Glu, and 0.7 (95% CI, 0.1 to 4.9; P=0.72) for Thr164Ile, respectively.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the present study, the maximal linkage was detected both in 2-point and multipoint analysis at the same chromosomal position corresponding to the D5S1480 microsatellite marker. In contrast, the linkage analysis of systolic blood pressure performed by Krushkal et al2 on the same chromosomal region implicated different markers located proximally to the telomere. This discrepancy is not surprising and may reflect several differences in ethnic (European versus American origin), demographic (age), and clinical (normotension versus hypertension) profile of the subjects between these studies.
To avoid a potential bias that may arise from a linkage analysis of a dichotomous trait based on arbitrary categorization (hypertension), we performed additional studies of systolic and diastolic blood pressures, detecting consistent linkage in the proximal segment of 5q31.1-qter chromosomal region for both qualitative and quantitative traits.
A qualitative-quantitative joint analysis has been postulated to increase the evidence for linkage, especially in case of multifactorial diseases,15 and it has been widely implemented in studies aiming to dissect genetic predisposition to atopic complex disorders.16,17
Consistent linkage signal obtained in 2-point and multipoint analysis narrowed down searches for candidate genes to the chromosomal segment assigned by D5S1480 and D5S500. Among several candidates for further positional analyses, we selected the ADRB2, the gene located in close proximity to the marker of the highest linkage. The priority was given to this candidate also in light of the well-documented role of the ADRB2 in blood pressure regulation and its essential contribution to the development of several cardiovascular and metabolic phenotypes related to hypertension.18
To test for the relationships between essential hypertension and the ADRB2, we performed association studies of 3 functional SNPs within the coding region of this gene. Arg16Gly, Gln27Glu, and Thr164Ile were selected for further analysis in light of the data regarding their influence on agonist-mediated receptor downregulation and affinity in vitro,18 as well as vascular desensitization in vivo.19 The lack of association of the ADRB2 polymorphisms with essential hypertension was evident in the TDT and verified by less conservative EV-FBAT test. Furthermore, these results were confirmed by the haplotype analysis. For the 2 common SNPs, our study had 86% power to detect association (P<0.05), with an odds ratio of 1.6.
The relationships between the polymorphisms of the ADRB2 gene and cardiovascular phenotypes have been assessed in European, American, Japanese, and African Caribbean populations,20–27 and the apparent lack of consistency in the results among these studies may be, at least partially, attributable to ethnic differences. Our results, analyzed in context of other European studies, are in agreement with the data obtained from English,20 French,21 and nondiabetic Swedish22 subjects. In contrast, association of the polymorphisms within the ADRB2 gene with blood pressure has been reported in Finnish,22 German, 24 and Austrian26 normotensive populations. It should be noted that all investigations on European normotensive subjects suggest the association of the ADRB2 with blood pressure, whereas the European studies involving hypertensive individuals are negative. One of the possible explanations for this discrepancy could be a pleiotropic effect exerted by the ADRB2. Its contribution to several cardiovascular and metabolic phenotypes (insulin resistance, obesity, heart failure)18 of significantly different prevalence among hypertensive and normotensive individuals is well documented and cannot be excluded as a factor confounding the relationship of the ADRB2 and blood pressure. Whether the suggested different role of the ADRB2 in normotensive and hypertensive populations may be caused by its synergistic influence on multiple cardiovascular/metabolic phenotypes (acting as potential cofounders) or represents a distinct genetic background of high and low blood pressure remains to be elucidated.
The question that remains to be answered is which locus within our candidate region may be responsible for the observed linkage. Several genes coding for proteins involved in blood pressure regulation and hypertensive complications located in close proximity to D5S1480 and D5S500—such as annexin VI, glutathione peroxidase 3 gene, platelet-derived growth factor receptor-ß gene, fibroblast growth factor-1, and glucocorticoid receptor gene—seem the most obvious positional candidates for further studies.
Perspectives
Our study implicates a short 7-cM segment on the long arm of the chromosome 5 as harboring a gene or genes for human essential hypertension. Furthermore, detailed haplotype analysis of three functional SNPs excluded ADRB2 as a causative gene. Further studies will focus on the remaining positional candidate genes, thus bringing closer the dissection of complex cardiovascular traits.
|
Acknowledgments |
|---|
We are grateful to physicians for their involvement in the recruitment of the families, Miroslawa Kasprzak and Danuta Pupar for their excellent assistance in DNA extraction, and Dr Wai Kwong Lee for advice on molecular analysis. This study was supported by International Society of Hypertension Clinical Research Fellowship (to M.T.) and by a British Heart Foundation Program grant (PG2000023) and the European Commission EURNETGEN QLG1-2000–01137 Program within EU Framework 5 (to A.F.D). F.J.C. is supported by a Wellcome Trust Traveling Fellowship.
Received January 28, 2002; first decision March 8, 2002; accepted June 28, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Lifton R, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001; 104: 545–556.[CrossRef][Medline] [Order article via Infotrieve]
2. Krushkal J, Xiong M, Ferrell R, Sing CF, Turner ST, Boerwinkle E. Linkage and association of adrenergic and dopamine receptor genes in the distal portion of the long arm of chromosome 5 with systolic blood pressure variation. Hum Mol Genet. 1998; 7: 1379–1383.
3. Krushkal J, Ferrell R, Mockrin SC, Turner ST, Sing CF, Boerwinkle E. Genome-wide linkage analysis of systolic blood pressure using highly discordant siblings. Circulation. 1999; 99: 1407–1410.
4. Rankinen T, An P, Rice T, Sun G, Chagnon YC, Gagnon J, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C. Genomic scan for exercise blood pressure in the health, risk factors, exercise training and genetics (Heritage) family study. Hypertension. 2001; 38: 30–37.
5. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999; 17: 151–183.[Medline] [Order article via Infotrieve]
6. Levy D, DeStefano A, Larson MG, O’Donnell CJ, Lifton RP, Gavras H, Cupples A, Myers RH. Evidence for a gene influencing blood pressure on chromosome 17: genome-scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham Heart Study. Hypertension. 2000; 36: 477–483.
7. Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfelt L, Arner P. Human ß2-adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte ß2-adrenoceptor function. J Clin Invest. 1997; 100: 3005–3013.[Medline] [Order article via Infotrieve]
8. O’Connell JR, Weeks D. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet. 1998; 63: 259–266.[CrossRef][Medline] [Order article via Infotrieve]
9. Elston RC. Introduction and overview: statistical methods in genetic epidemiology. Stat Methods Med Res. 2000; 9: 527–541.
10. Lange K. The affected sib-pair method using identity by state relations. Am J Hum Genet. 1986; 39: 148–150.[Medline] [Order article via Infotrieve]
11. Duffy DL. SIB-PAIR 0.98.8: A Program for Elementary Genetical Analysis. Herston, Queensland: Queensland Institute of Medical Research; 1995–1999.
12. Spielman RS, Ewens WJ. The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genet. 1996; 59: 983–989.[Medline] [Order article via Infotrieve]
13. Lake SL, Blacker D, Laird NM. Family-based tests of association in the presence of linkage. Am J Hum Genet. 2000; 67: 1515–1525.[CrossRef][Medline] [Order article via Infotrieve]
14. Clayton D. A generalization of the transmission/disequilibrium test for uncertain-haplotype transmission. Am J Hum Genet. 1999; 65: 1170–1177.[CrossRef][Medline] [Order article via Infotrieve]
15. Williams JT, Van Eerdewegh P, Almasy L, Blangero J. Joint multipoint linkage analysis of multivariate qualitative and quantitative traits. I. likelihood formulation and simulation results. Am J Hum Genet. 1999; 65: 1134–1147.[CrossRef][Medline] [Order article via Infotrieve]
16. Palmer LJ, Barnes KC, Burton PR, Chen H, Cookson WOCM, Collaborative Study on the Genetics of Asthma, Deichmann KA, Elston RC, Holloway JW, Jacobs KB, Laitinen T, Wjst M. Meta-analysis for linkage to asthma and atopy in the chromosome 5q31-33 candidate region. Hum Mol Genet. 2001; 10: 891–899.
17. Soderhall C, Bradley M, Kockum I, Wahlgren CF, Luthman H, Nordenskjold M. Linkage and association to candidate regions in Swedish atopic dermatitis families. Hum Genet. 2001; 109: 129–135.[CrossRef][Medline] [Order article via Infotrieve]
18. Bray M, Boerwinkle E. The role of ß2-adrenergic receptor variation in human hypertension. Curr Hypertens Rep. 2000; 2: 39–43.[Medline] [Order article via Infotrieve]
19. Dishy V, Sofowora GG, Xie H, Kim RB, Byrne DW, Stein CM, Wood AJJ. The effect of common polymorphisms of the ß2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med. 2001; 345: 1030–1035.
20. Jia H, Sharma P, Hopper R, Dickerson C, Lloyd DD, Brown MJ. ß2-Adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. J Hypertens. 2000; 18: 687–693.[CrossRef][Medline] [Order article via Infotrieve]
21. Hermann SM, Nicaud V, Tiret L, Evans A, Kee F, Ruidavets JB, Arveiler D, Luc G, Morrison C, Hoehe M, Paul M, Cambien F. Polymorphisms of the ß2-adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. J Hypertens. 2002; 20: 229–235.[CrossRef][Medline] [Order article via Infotrieve]
22. Bengtsson K, Orho-Melander M, Melander O, Lindblad U, Ranstam J, Rastam L, Groop L. ß2-Adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension. 2001; 37: 1303–1308.
23. Kato N, Sugiyama T, Morita H, Kurihara H, Sato T, Yamori Y, Yazaki Y. Association analysis of ß2-adrenergic receptor polymorphisms with hypertension in Japanese. Hypertension. 2001; 37: 286–292.
24. Busjahn A, Guo-Hua L, Faulhaber HD, Rosenthal M, Becker A, Jeschke E, Schuster H, Timmermann B, Hoehe MR, Luft FC. ß2-Adrenergic receptor gene variations, blood pressure, and heart size in normal twins. Hypertension. 2000; 35: 555–560.
25. Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, Turner ST, Boerwinkle E. Positional genomic analysis identifies the ß2-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation. 2000; 101: 2877–2882.
26. Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, Luft FC, Hoehe MR, Skrabal F. ß2-Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension. 1999; 33: 1425–1430.
27. Kotanko P, Binder A, Tasker J, DeFreitas P, Kamdar S, Clark AJL, Skrabal F, Caulfield M. Essential hypertension in African Caribbeans associates with a variant of the ß2-adrenoceptor. Hypertension. 1997; 30: 773–776.
This article has been cited by other articles:
 |
|
 |
|
  M. Tomaszewski, F. J. Charchar, M. D. Lynch, S. Padmanabhan, W. Y.S. Wang, W. H. Miller, W. Grzeszczak, C. Maric, E. Zukowska-Szczechowska, and A. F. Dominiczak Fibroblast Growth Factor 1 Gene and Hypertension: From the Quantitative Trait Locus to Positional Analysis Circulation, October 23, 2007; 116(17): 1915 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pojoga, N. S. Kolatkar, J. S. Williams, T. S. Perlstein, X. Jeunemaitre, N. J. Brown, P. N. Hopkins, B. A. Raby, and G. H. Williams {beta}-2 Adrenergic Receptor Diplotype Defines a Subset of Salt-Sensitive Hypertension Hypertension, November 1, 2006; 48(5): 892 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Poole, H. Snieder, H. C. Davis, and F. A. Treiber Anger suppression and adiposity modulate association between ADRB2 haplotype and cardiovascular stress reactivity. Psychosom Med, March 1, 2006; 68(2): 207 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tomaszewski, F. J. Charchar, B. Lacka, U. Pesonen, W. Y.S. Wang, E. Zukowska-Szczechowska, W. Grzeszczak, and A. F. Dominiczak Epistatic Interaction Between {beta}2-Adrenergic Receptor and Neuropeptide Y Genes Influences LDL-Cholesterol in Hypertension Hypertension, November 1, 2004; 44(5): 689 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Kirstein and P. A. Insel Autonomic Nervous System Pharmacogenomics: A Progress Report Pharmacol. Rev., March 1, 2004; 56(1): 31 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Charchar, M. Tomaszewski, B. Lacka, J. Zakrzewski, E. Zukowska-Szczechowska, W. Grzeszczak, and A. F. Dominiczak Association of the Human Y Chromosome with Cholesterol Levels in the General Population Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 308 - 312. [Abstract] [Full Text]
|
|
|
|
|
|
A. C. Pereira, M. S. Floriano, G. F.A. Mota, R. S. Cunha, F. L. Herkenhoff, J. G. Mill, and J. E. Krieger {beta}2 Adrenoceptor Functional Gene Variants, Obesity, and Blood Pressure Level Interactions in the General Population Hypertension, October 1, 2003; 42(4): 685 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Castellano, F. Rossi, M. Giacche, C. Perani, F. Rivadossi, M. L. Muiesan, M. Salvetti, M. Beschi, D. Rizzoni, and E. Agabiti-Rosei {beta}2-Adrenergic Receptor Gene Polymorphism, Age, and Cardiovascular Phenotypes Hypertension, February 1, 2003; 41(2): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||